Hasil Pencarian  ::  Simpan CSV :: Kembali

"BackgroundProdromal factors of Guillain-Barre syndrome (GBS) are often associated with previous viral infection (60%). The ailment supported by the acquired immunomediated disorder concept. Viral hepatitis is very rarely found in GBS, preceded by cytomegalovirus (15-18%), Campylobacter jejuni (28%), and Epstein-Barr virus (5%). There is no specific etiology of GBS because those viruses usually appear sporadically (subclinically). All hepatitis virus infection can cause neurological complications, including GBS.Case ReportWe report two cases of hepatitis A virus infection (HAV) in GBS patients in Dr. Sardjito General Hospital during 5 years of observation (1996-2000) from 92 GBS patients. The diagnosis of HAV was based on more than 2 times increment of transaminase enzyme, positive IgM anti HAV, negative HbsAg, and negative IgM ami HCV. The diagnosis of GBS was based on clinical symptoms of acute generalized paralysis, cerebrospinal fluid examination, and electromyelography. In both cases, sub-clinical and sporadic symptoms appeared several days before paralysis, which makes it more likely that the prodromal period of GBS occurred at the same time of HAV incubation period.DiscussionThe incidence of HAV in GBS patients during 5 years of observation was 2%. This corresponds with the case reported by Verona et al, 1996 and Pelletier et al, 1985, i.e. the presence of peripheral neuropathy (n. facialis and n. occulomotorius). Possible alternative pathways for hepatitis virus complicating as GBS are perivascular and endometrial peripheral nerve infiltration by mononuclear cells, T cell sensitization, stimulation of IL-2 growth factor surface receptor, and B cell stimulation. All of the conditions mentioned above causes necrotizing arteritis, vascular occlusion, and at the end, segmental demyelinization. Hepatitis virus may replicate in the central nervous system or peripheral nervous system, subsequently developing into multiple neuropathy disorder and poly arteritis.ConclusionThe diagnoses of HAV and GBS in both cases were established. HAV is one of several viruses that may trigger GBS. In both cases, HAV infection was sub-clinical and sporadic. Symptoms of hepatitis infection subsided along with improvements in the patient's neurological status. Acute viral hepatitis has a wide clinical spectrum and laboratory manifestation that is in accordance with the severity, varying from unclear symptom (anicteric) to jaundice. Acute hepatitis A, B, C infections have the same symptoms in general. However, hepatitis B and C tend to be more severe. The mildest symptoms are transaminase enzyme level increment, no jaundice, gastrointestinal symptoms, flu-like symptoms, and sometimes it can not be diagnosed. The more severe symptoms are jaundice with obvious generalized symptoms.' The incidence of hepatitis A is difficult to be determined accurately because of its characters, i.e. sporadic, endemic, and has a high rate of asymptomatic infection.23-4"

"ABSTRAK<

Karsinoma hepatoseluler (KHS) merupakan karsinoma primer tersering pada sel hati. Sebagian besar KHS disebabkan oleh virus hepatitis B (VHB) dan virus hepatitis C (VHC) yang memiliki patogenesis yang berbeda dalam menyebabkan KHS. Alfa-fetoprotein (AFP) sebagai penanda tumor pada KHS dan dipengaruhi oleh berbagai faktor, salah satunya status infeksi. Berbagai penelitian sudah dilakukan untuk mengetahui pengaruh pengaruh jenis virus penyebab KHS dengan kadar AFP namun hasilnya sangat beragam. Berdasarkan hal tersebut dan ditambah dengan belum adanya penelitian serupa yang menggunakan data pasien di Indonesia maka penelitian ini bertujuan untuk membandingkan kadar AFP pada pasien KHS terkait infeksi VHB terhadap VHC. Penelitian ini dilakukan dengan desain studi potong lintang menggunakan 199 data AFP pasien KHS yang terdiri dari 129 kasus KHS terkait VHB dan 70 kasus KHS terkait VHC. Dari penelitian ini didapatkan sebanyak 97% dan 87.3% pasien KHS terkait VHC dan VHB mengalami peningkatan kadar AFP secara berurutan. Nilai median kadar AFP pada pasien KHS terkait VHB adalah 419 IU/mL sedangkan pada pasien KHS terkait VHC sebesar 400 IU/mL. Perbedaan nilai tersebut memiliki nilai p = 0.97 dalam uji Mann-Whitney U sehingga disimpulan tidak ada perbedaan bermakna pada rerata kadar AFP antara pasien KHS terkait VHB dibanding dengan VHC.

---

ABSTRACT

Hepatocellular carcinoma (HCC) is the most primary common carcinoma in liver cells. Most HCC are caused by the hepatitis B virus and hepatitis C that have different pathogenesis in causing carcinoma. Alpha-fetoprotein as tumor marker in HCC is influenced by various factors, one of which is infection status. Various studies have been carried out to determine the influence of the types of viruses causing HCC with AFP levels but the results are very diverse. Based on this and coupled with the absence of similar studies using patient data in Indonesia, this study aims to compare AFP levels in HCC patients related to HBV and HCV. Using cross-sectional design, this study included 199 data of AFP in patient with HCC comprises of 129 cases of HCC related to HBV and 70 cases of HCC related to HCV. From this study, it was found that 97% and 87.3% of HCC patients related to HCV and HBV experienced an increase in AFP levels consecutively. The median value of AFP levels in HBV-related HCC patients was 419 IU / mL while in HCV-related HCC patients was 400 IU / mL. The difference in value has a p value = 0.97 in the Mann-Whitney U test thus it is concluded that there is no significant difference in AFP levels between HBV-related HCC patients compared with HCV-related HCC.

"

"Genotipe virus hepatitis B (VHB) mempunyai hubungan yang erat dengan prognosis dan terapinya serta diperlukan untuk studi epidemiologi. Pemeriksaan ini hanya bisa dikerjakan di kota-kota besar saja karena kesulitan pengiriman sampel akibat masalah geografis maupun fasilitas. Tujuan penelitian ini adalah untuk mengetahui apakah genotipe VHB dapat ditentukan dari serum kering pada kertas saring dan membandingkan hasil tersebut dengan serum yang diambil langsung dari pasien hepatitis B kronik (HBK) dan hepatoma. Dua puluh tiga sampel dapat diambil dari pasien HBK dan konsentrasi DNA VHB di tentukan dengan Cobas Amplicor HBM (Roche Diagnostics GmBH, Germany) kemudian diteteskan pada kertas saring (3 x 1 cm). Setelah dikeringkan dalam kantong plastik, diletakkan dalam amplop tertutup dan disimpan selama 1 minggu dalam suhu kamar (27 – 33 oC). Ekstraksi DNA dilakukan dari kertas saring tersebut setelah diinkubasi dan penentuan genotipe VHB dilakukan dengan PCR menggunakan primer-primer spesifik. Untuk perbandingan, telah didapatkan 20 sampel pasien HBK-HBe (+) dan 29 sampel pasien hepatoma yang tidak dikeringkan. Genotipe VHB dapat dideteksi pada 18/23 (78,2%) serum kering pada kertas saring sedangkan pada serum yang tidak dikeringkan, dari pasien HBK-HBe(+) 20/20 (100%) sampel terdeteksi dan dari pasien hepatoma 24/29 (82,7%) sampel. Proporsi genotipe yang terdeteksi sesuai dengan proporsi genotipe yang pernah dilaporkan di Indonesia. Kesimpulan penelitian ini adalah genotipe VHB dapat dideteksi dari serum kering pada kertas saring yang disimpan selama 1 minggu. (Med J Indones 2005; 14: 215-9)

---

HBV genotype has a close association with prognosis and therapy as well as for epidemiology study. However, this examination can be done only in large cities that are not practical to send serum sample due to geographical burden and facilities. The aim of this study is to know whether HBV genotype can be determined from dried and stored serum on filter paper and compare the result with sera drawn directly from chronic hepatitis B (CHB) and hepatoma patients. Twenty-three serum samples were obtained from CHB patients. HBV DNA were quantitatively determined with Cobas Amplicor HBM (Roche Diagnostics GmBH, Germany) and dropped on to 3 x 1 cm filter papers. After allowed to dry in a plastic clip, it were put in a closed envelope then stored for 1 week in room condition (27 – 33 oC). DNA extraction were done from the filter papers after a short incubation period and HBV genotypes were determined with PCR and specific primers. For comparison, 20 CHB-Hbe(+) samples and 29 hepatoma samples were drawn directly and not dried. HBV genotype were detected in 18/23 (78.2%) from dried serum samples on filter paper while in sera that were not stored, from CHB-HBe(+) samples, 20/20 (100%) could be determined while from hepatoma patients, 24/29 (82.7%) samples. The proportion of genotype were in line with other reported HBV genotype examination for Indonesia. It is concluded that detection of HBV genotype can be done from dried serum in filter paper and stored for 1 week. (Med J Indones 2005; 14: 215-9)"

"Amplifikasi DNA virus hepatitis B (VHB) dari sampel plasma sulit dilakukan apabila kadar DNA VHB <10.000 kopi/ml. Sehingga, langkah awal ekstraksi menjadi penting bagi keberhasilan amplifikasi dan sekuensing. Peningkatan konsentrasi DNA dalam jumlah yang cukup dan berkualitas baik memerlukan metode isolasi yang optimal. Tujuan penelitian ini adalah mendapatkan teknik isolasi DNA yang optimal untuk menghasilkan DNA VHB dalam jumlah yang cukup sehingga dapat digunakan untuk mendeteksi perubahan genetik gen polimerase VHB terkait resistensi obat antivirus pada kasus hepatitis B kronik. Optimasi prosedur penanganan sampel untuk mengekstraksi partikel DNA VHB dilakukan dengan mengisolasi sampel plasma dengan kadar virus 105 kopi/ml menggunakan delapan perlakuan yang berbeda yaitu 1 ml dan 200 µL plasma disentrifugasi 4000xg selama 20 menit pada suhu 25°C (P1 dan P2), 1 ml dan 200 µL plasma disentrifugasi 16000xg selama 1 jam pada suhu 4°C (P3 dan P4), 1 ml plasma disentrifugasi 21000xg selama 1 jam pada suhu 4°C (P5), 1 ml plasma dalam PEG6000 20% diinkubasi semalaman pada 2-8°C kemudian disentrifugasi 21000xg selama 1 jam pada suhu 4°C (P6), 1 ml plasma dalam PEG6000 20% dan NaCl 0.5M diinkubasi semalaman pada 2-8oC kemudian disentrifugasi 21000xg selama 1 jam pada suhu 4°C (P7), dan 200 µL sampel plasma tanpa penambahan perlakuan (P8). Kadar virus diukur menggunakan kuantitatif realtime PCR, dan hasil dari setiap perlakuan sampel dibandingkan dengan kontrol (P8). Uji simulasi dilakukan pada sampel plasma dengan kadar virus 105; 104; 103 dan 102 kopi/ml yang diberikan perlakuan 3 (P3) yang dipilih berdasarkan hasil sebelumnya, DNA kemudian disekuensing untuk dianalisis mutasi resistensinya terhadap obat antivirus dan hasilnya dibandingkan dengan sampel yang tanpa diberikan perlakuan. Hasil menunjukkan bahwa terjadi peningkatan konsentrasi DNA pada rerata sampel yang diisolasi menggunakan P3 jika dibandingkan dengan kontrol (P8). Sedangkan hasil sekuensing untuk analisis mutasi pada gen polimerase terkait resistensi terhadap obat antivirus dapat dilakukan pada sampel dengan kadar virus 105; 104; 103 kopi/ml baik yang diberikan perlakuan maupun tanpa perlakuan. Namun, sampel dengan kadar virus 102 kopi/ml hanya dapat dianalisis mutasi resistensinya pada sampel yang ditambahkan perlakuan 3 (P3). Kesimpulan: 1 ml plasma yang disentrifugasi 16000xg selama 1 jam pada suhu 4°C (perlakuan 3) merupakan metode isolasi DNA yang mampu meningkatkan perolehan DNA secara optimal dari sampel plasma penderita hepatitis B kronik, sehingga analisis resistensi terhadap obat antivirus menggunakan teknik in-house assay dapat di lakukan pada sampel dengan kadar virus <10.000 kopi DNA/ml.

---

The amplification of hepatitis B virus DNA from plasma samples is difficult when HBV DNA levels <10.000 copies/ml. Thus, the initial step of extraction become crucial for the success of amplification and sequencing. Increasing concentrations of DNA in sufficient quantity and good quality need an optimal isolation method. The aim of this study is to obtain an optimal DNA isolation technique and generate HBV DNA in sufficient quantities, so that it can be used to detect genetic changes of HBV polymerase gene related to drugs resistance on chronic hepatitis B. The optimization of sample handling procedure for extracting HBV DNA particles were performed by isolating plasma samples with viral load 105 copies/ml using eight different kinds of treatment are 1 ml and 200 µL of plasma was centrifuged at 4000×g for 20 minutes at 25°C (P1 and P2); 1 ml and 200 µL of plasma centrifuged at 16000×g for 1 hour at 4°C (P3 and P4); 1 ml of plasma centrifuged at 21000×g for 1 hour at 4°C (P5); 1 ml of plasma in 20% PEG6000 were incubated overnight at 2-8°C then centrifuged at 21000xg for 1 hour at 4°C (P6), 1 ml of plasma in 20% PEG6000 and 0.5M NaCl were incubated overnight at 2-8oC then centrifuged at 21000xg for 1 hour at 4°C (P7), and 200 µL of plasma without treatment (P8). Hepatitis B virus level were measured using quantitative real-time PCR, and the results of each treatment compared to the control samples (P8). Simulation test performed on plasma samples with grading of virus level (i.e 105; 104; 103 and 102 copies/ml) were given treatment 3 (P3) were selected based on previous results, the DNA was sequenced and then analyzed for drugs resistance and the results were compared with samples without treatment.

Result showed that an increasing in average concentration of DNA samples was isolated using the P3 when compared with controls (P8). While the results of sequencing for analysis of mutations in polymerase gene associated with drugs resistance can be performed on samples with virus level 105; 104; 103 copies/ml were given either treatment or no treatment. However, samples with virus level 102 copies/ml can be analyzed only

on treatment samples.

Conclusion: 1 ml plasma were centrifuged at 16000xg for 1 h at 4°C (treatment 3) is a DNA isolation method that can improve the recovery of optimal DNA from plasma samples of patients with chronic hepatitis B, so that the analysis of drug resistance using in-house assay techniques can be done on samples with virus levels <10,000 copies/ml."

"The frequencies of HBsAg and. Anti-HBs among medical/paramedical personnel were compared with that of control group. The health oare personnels numbered 515 persons who were taken from the medical and paramedical staffs of the Dept. Medicine, Dept.Obstetry & Gynaecology. Dept. Dentistry, Dept.Pathology, and Blood Transfusion Service from Cipto Mangunkusumo General Hospital and the Indonesian Red Cross, Jakarta Branch respectively. The oontrol group consisted of 503 non medical personnels who conscripted to give blood as a pre-requisite to obtaining driving license at Jakarta Metropolitan Polioe Headquarter., and who donated their blood to the Indonesian Red Cross for other rea. sons. None of the control group were neither classified as paid donors nor regular donors. By using RPHA and PHA methods, ree onfirmed by staffs of Tokyo Metropolitan Institute of Medical Science, the frequencies of HBsAg and Anti-HBs among the study and the oontrol groups were found 3,1 % , and 49,1 % (study group), and 2,8 % and 42,5 % ( control group) respectively. The frequency of anti-HBs from the study group differ significan tly with the frequency of Anti-HBs from the control group. One respondent contracted double HBV infection, possibly from two different subtypes."

"Chronic hepatitis due to hepatitis B virus (HBV) or hepatitis C virus (HCP) is still a major problem in terms of progressive liver damage, prevention and therapy in most parts ofthe world. Unfortunately, to date, there is still no specific and effective therapy for HBV. No therapy can be given to carrier; non-replicative and asymptomatic patients of chronic HBV infection. Lamivudine or alpha-interferon can be used for treatment of compensated chronic hepatitis B infection with significant increase of aminotransferase. Approximately 40 % of patients can have seroconversion with this form of therapy. Chronic hepatitis D virus injection can be treat with alpha-interferon and in the final stage, may undergo liver transplantation. For chronic hepatitis C virus infection, alpha-interferon with ribavirin have been shown to have a better efficacy than afpha-interferon alone where the efficacy can reach 39-49 %."

"Chronic hepatitis B is still a major health problem in Indonesia. Unfortunately, to date, treatment of chronic HBV (Hepatitis B virus) infection had not shown satisfactory result. Monotherapy with alpha interferon or lamivudine have been widely used as treatment of chronic HBV. However, treatment response to Alpha interferon in Asian people was not satisfactory (15% - 20%), while monotherapy with lamivudine was not sufficient to eradicate HBV in chronically infected patients and commonly induce drug resistance. The occurrence of chronic hepatitis B resistant to lamivudine had encouraged development of newer agents such as adefovir, entecavir, emtricitabine and nucleoside analog. New therapeutic strategy using combination therapy should be considered if there is no sufficient response to monotherapy"